awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q35988523-E80F52A9-2D66-4224-8CA4-FCACEB20A587
Q35988523-E80F52A9-2D66-4224-8CA4-FCACEB20A587
BestRank
Statement
http://www.wikidata.org/entity/statement/Q35988523-E80F52A9-2D66-4224-8CA4-FCACEB20A587
Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase.
P2860
Q35988523-E80F52A9-2D66-4224-8CA4-FCACEB20A587
BestRank
Statement
http://www.wikidata.org/entity/statement/Q35988523-E80F52A9-2D66-4224-8CA4-FCACEB20A587
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
265444ccd6e00136703e0d54e5574ceccf7c6d3d
P2860
Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia.